- Home
- CBNA vs PLX Comparison
CBNA vs PLX Comparison
Compare CBNA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- PLX
- Stock Information
- Founded
- CBNA 2006
- PLX 1993
- Country
- CBNA United States
- PLX Israel
- Employees
- CBNA N/A
- PLX N/A
- Industry
- CBNA
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBNA
- PLX Health Care
- Exchange
- CBNA NYSE
- PLX Nasdaq
- Market Cap
- CBNA 159.8M
- PLX 160.2M
- IPO Year
- CBNA 2024
- PLX 1998
- Fundamental
- Price
- CBNA $24.00
- PLX $2.57
- Analyst Decision
- CBNA Buy
- PLX Strong Buy
- Analyst Count
- CBNA 3
- PLX 1
- Target Price
- CBNA $29.67
- PLX $15.00
- AVG Volume (30 Days)
- CBNA 10.1K
- PLX 791.9K
- Earning Date
- CBNA 05-15-2025
- PLX 03-17-2025
- Dividend Yield
- CBNA N/A
- PLX N/A
- EPS Growth
- CBNA 115.79
- PLX N/A
- EPS
- CBNA 4.17
- PLX 0.04
- Revenue
- CBNA $53,113,000.00
- PLX $53,399,000.00
- Revenue This Year
- CBNA N/A
- PLX $67.17
- Revenue Next Year
- CBNA $28.23
- PLX $55.31
- P/E Ratio
- CBNA $5.82
- PLX $69.84
- Revenue Growth
- CBNA 74.81
- PLX N/A
- 52 Week Low
- CBNA $20.10
- PLX $0.82
- 52 Week High
- CBNA $27.56
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- PLX 58.33
- Support Level
- CBNA N/A
- PLX $2.24
- Resistance Level
- CBNA N/A
- PLX $2.62
- Average True Range (ATR)
- CBNA 0.00
- PLX 0.15
- MACD
- CBNA 0.00
- PLX 0.03
- Stochastic Oscillator
- CBNA 0.00
- PLX 82.08
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.